Big Pharma-backed Nuvig Therapeutics has halted one of two trials for its sole clinical asset after determining the program ...
Eli Lilly-backed TRex Bio is aiming for a $111.3 million IPO, while hypertension-focused Retension Pharmaceuticals hopes for ...
Kairos Pharma is moving prostate cancer prospect ENV-105 into an earlier line of treatment in response to midphase survival ...
Forbion has touted its “landmark” 2.3 billion euro ($2.6 billion) fundraise across two funds as a new record for the European ...
Abbott has been given U.S. clearance for new updates to its CardioMEMS HF System that allow for patient-facing capabilities ...
A phase 3 lung cancer study of ArriVent BioPharma’s EGFR inhibitor has missed its primary endpoint, sending the biotech’s stock down 57% in early trading.
Using a short lapidated peptide (SLiP) developed by Mimetic Medicines disrupted a crucial voltage-gated sodium channel ...
Genentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver ...
The FDA has approved a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease. | The FDA has approved a surgically implanted pulmonary heart valve ...
Vaxcyte has seen its stock jump after the biotech’s 31-valent pneumococcal vaccine candidate went head-to-head with Pfizer’s Prevnar 20 and Merck & Co.’s Capvaxive in a phase 3 contest. The biotech ...
Sanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage im | Sanofi is paying Regeneron $1 billion ...
As Foghorn digested the end of the Lilly partnership, the biotech said it was laying off 40% of its workforce, while “further ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results